The Pharmaceutical Advertising Advisory Board (PAAB) is an independent not-for-profit organization funded on a fee-for-service model. It is the only regulator whose preclearance service is recognized by Health Canada for advertising directed to healthcare professionals. PAAB works to protect Canadians by ensuring that healthcare product advertising meets the regulatory, scientific, therapeutic, and ethical standards outlined in the Code of Advertising Acceptance. All PAAB approved materials bear the PAAB logo.
Please either speak with a PAAB file coordinator or send an email to firstname.lastname@example.org if considering ARO-2 for an APS that does not meet BOTH of the following criteria (to ensure that we can deliver the first response within 2 business days):
As a general guide, a “detailed assessment” entails needing to read the entire reference to determine its validity (e.g., clinical trials, surveys) and/or to ensure that the promoted elements are not overly selective. Factors that typically determine whether a detailed assessment will be required include whether the reference has been used for similar claims in prior PAAB approved materials, and the nature of the reference (e.g., new studies & surveys generally require a detailed assessment). Additional information will be provided in the upcoming version of the Submission Guide.
¥ Feature is only available on AROs
Starting in 2023, all PAAB fees will be adjusted annually by the prior year’s change in cost of living. These adjustments will impact all files submitted as of the first working day of each year. All fees are exclusive of HST
Starting in 2023, all PAAB fees will be adjusted annually by the prior year’s change in cost of living. All fees are exclusive of HST.
Fees are invoiced after the first review letter has been sent. Fees are for the cost of the review and not for the acceptance of the APS. Once a piece has an approval number, we consider the approval process to have been completed for the fee that was assessed. Any revisions after that will be treated as a new submission with a new file number and billed a full fee. A review of prescribing information at launch or when revised will be billed an "All APS" fee.
All APS review files which have not received any response for over 180-days will be closed and any revisions following the 180-day period will be assigned a new file number and subject to a new fee.
All APS review files that are not completed within a period of twelve months will be assigned a new file number and subject to a new fee.
Once an acceptance number is issued, the file is considered completed and further revisions to the APS would require a new file number and subject to a new fee.
Invoices are payable within 30 days; advertisers with outstanding balances may be required to clear their accounts before new reviews can begin. Our BN is 104174743.
Questions about fees should be directed to the PAAB office: 203-1305 Pickering Parkway, ON L1V 3P2.
Tel: (905) 509-2275
Send email to email@example.com.
Advisory: Increased specificity in series fee criteria